SG11202004500YA - Immune response profiling of tumor-derived exosomes for cancer diagnosis - Google Patents
Immune response profiling of tumor-derived exosomes for cancer diagnosisInfo
- Publication number
- SG11202004500YA SG11202004500YA SG11202004500YA SG11202004500YA SG11202004500YA SG 11202004500Y A SG11202004500Y A SG 11202004500YA SG 11202004500Y A SG11202004500Y A SG 11202004500YA SG 11202004500Y A SG11202004500Y A SG 11202004500YA SG 11202004500Y A SG11202004500Y A SG 11202004500YA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- immune response
- cancer diagnosis
- derived exosomes
- response profiling
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201710131X | 2017-12-06 | ||
| PCT/SG2018/050594 WO2019112520A1 (en) | 2017-12-06 | 2018-12-06 | Immune response profiling of tumor-derived exosomes for cancer diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004500YA true SG11202004500YA (en) | 2020-06-29 |
Family
ID=66749892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004500YA SG11202004500YA (en) | 2017-12-06 | 2018-12-06 | Immune response profiling of tumor-derived exosomes for cancer diagnosis |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210223251A1 (en) |
| CN (1) | CN111433608A (en) |
| SG (1) | SG11202004500YA (en) |
| WO (1) | WO2019112520A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102284336B1 (en) * | 2019-08-06 | 2021-08-03 | 한국원자력연구원 | Exosome derived from radiated cancer cell, cancer vaccine comprising dendritic cell prepared by using the same and preparing method thereof |
| CN111909900A (en) * | 2020-07-19 | 2020-11-10 | 东南大学 | Method for enhancing immune response based on in-situ self-assembly intelligent nanoparticles |
| CN112415206B (en) * | 2020-10-23 | 2023-08-18 | 上海良润生物医药科技有限公司 | Application of CD171 protein in exosome as tumor metastasis diagnosis marker |
| CN113960313B (en) * | 2021-12-22 | 2022-04-12 | 上海思路迪医学检验所有限公司 | Exosome ALK fusion protein magnetic immunochemiluminescence detection kit |
| CN116519926A (en) * | 2022-03-15 | 2023-08-01 | 上海君赛生物科技有限公司 | Tumor specific immune cell marker and application thereof |
| CN116660195B (en) * | 2023-04-27 | 2024-07-09 | 中国人民解放军海军军医大学 | System and method for identifying exosomes of different cancer sources based on infrared spectrum characteristics |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7640114B2 (en) * | 2003-05-21 | 2009-12-29 | The Wistar Institute Of Anatomy & Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| GB201418242D0 (en) * | 2014-10-15 | 2014-11-26 | Univ Cape Town | Genetic biomarkers and method for evaluating cancers |
-
2018
- 2018-12-06 SG SG11202004500YA patent/SG11202004500YA/en unknown
- 2018-12-06 US US16/761,827 patent/US20210223251A1/en not_active Abandoned
- 2018-12-06 WO PCT/SG2018/050594 patent/WO2019112520A1/en active Application Filing
- 2018-12-06 CN CN201880077615.0A patent/CN111433608A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111433608A (en) | 2020-07-17 |
| WO2019112520A1 (en) | 2019-06-13 |
| US20210223251A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251257A1 (en) | Use of exosomes for the treatment of disease | |
| SG11202004500YA (en) | Immune response profiling of tumor-derived exosomes for cancer diagnosis | |
| IL289297A (en) | Adjuvant treatment of her2-positive breast cancer | |
| IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
| HK1253082A1 (en) | Method of diagnosis of breast cancer | |
| GB2579328B (en) | Breast cancer detection | |
| PL3474918T3 (en) | Breast shield unit | |
| IL266324A (en) | Treatment of her2-positive breast cancer | |
| SG10201913528PA (en) | Methods of diagnosing cancer | |
| SG11201706544SA (en) | Breast shield | |
| IL258671A (en) | Therapeutic agent for breast cancer | |
| IL247940B (en) | Treatment of brca1-defective cancer or resistant cancers | |
| SG11201701076TA (en) | Diagnosis of cancer | |
| GB201602210D0 (en) | Detection of cancer | |
| PL3152576T3 (en) | Use of tm9sf4 as a biomarker for tumor associated exosomes | |
| EP3839513C0 (en) | Use of dna-transcription factor complexes for cancer detection | |
| GB201814350D0 (en) | Diagnosis of cancer | |
| HK1243434A1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
| IL268274A (en) | Methods of diagnosing malignant diseases | |
| DK3277325T3 (en) | COMBINATION IMMUNE THERAPY FOR CANCER | |
| HK1248730A1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
| GB201810858D0 (en) | Determination of cancers | |
| GB201718806D0 (en) | Breast cancer treatment | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer |